The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Low dosage combination treatment with metformin and simvastatin inhibits obesity-promoted pancreatic cancer development in male KrasG12D mice
Open accessAbstract
Pancreatic ductal adenocarcinoma (PDAC), a highly lethal disease with limited therapeutic options, may benefit from repurposing of FDA-approved drugs in preventive or interceptive strategies in high-risk populations. Previous animal studies demonstrated that the use of metformin and statins as single agents at relatively high doses restrained PDAC development. Here, four-week-old mice expressing KrasG12D in all pancreatic lineages (KC mice) and fed an obesogenic high fat, high calorie diet that promotes early PDAC development were randomized onto low dosage metformin, simvastatin, or both drugs in combination administered orally. Dual treatment attenuated weight gain, fibro-inflammation, and development of advanced PDAC precursor lesions (pancreatic intraepithelial neoplasia [PanIN]-3) in male KC mice, without significant effect in females or when administered individually. Dual-treated KC mice had reduced proliferation of PanIN cells and decreased transcriptional activity of the Hippo effectors, YAP and TAZ, which are important regulators of PDAC development. Metformin and simvastatin also synergistically inhibited colony formation of pancreatic cancer cells in vitro. Together, our data demonstrated that a combination of low doses of metformin and simvastatin inhibits PDAC development and imply that both drugs are promising agents for being tested in clinical trials for preventing pancreatic cancer progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“simvastatin and metformin, in combination only, decrease YAP/TAZ transcriptional activity”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Teper et al., 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“four-week-old obese KRASG12D mutant male mice that were treated with simvastatin in combination with metformin, which, compared to female mice or mice treated with either simvastatin or metformin, had a lower risk of PanIn-3”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Teper et al., 2023
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Hippo pathway in organ size control, tissue homeostasis, and cancer
Yu, F.-X., Zhao, B., & Guan, K.-L. (2015) · Cell · doi:10.1016/j.cell.2015.10.044 · Cited by 2,206
The emerging roles of YAP and TAZ in cancer
Moroishi, T., Hansen, C. G., & Guan, K.-L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3876 · Cited by 1,145 · cited 1×
“We could not detect a consistent shift towards cytoplasmic localization of YAP or TAZ (indicating inhibition of transcriptional activity 35 ) within PanIN cells in KC mice treated with metformin and simvastatin, which may be due, in part, to the cell context-specific, transient nature of nucleo ‐…”
Hruban, R. H., Adsay, N. V., Albores–Saavedra, J., Compton, C., Garrett, E. S., Goodman, S. N., Kern, S. E., Klimstra, D. S., Klöppel, G., Longnecker, D. S., et al. (2001) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200105000-00003 · Cited by 1,126
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
Hruban, R. H., Adsay, N. V., Albores-Saavedra, J., Anver, M. R., Biankin, A. V., Boivin, G. P., Furth, E. E., Furukawa, T., Klein, A., Klimstra, D. S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2168 · Cited by 414 · cited 1×
“For the quantification of ADM and PanIN lesions histopathologic criteria as recommended elsewhere were used [47, 48].”
Statin Therapy: Review of Safety and Potential Side Effects.
Ramkumar, S., Raghunath, A., & Raghunath, S. (2016) · PubMed · doi:10.6515/acs20160611a · Cited by 358 · cited 1×
“The impetus for investigating lower doses of both drugs was the known risk of clinically significant side effects of metformin and simvastatin in a subset of patients 16,17 .”
Cited by
Halabitska, I., Babinets, L., Oksenych, V., & Kamyshnyi, O. (2024) · Biomedicines · doi:10.3390/biomedicines12081630 · Cited by 53
“Met-formin’s pharmacological activity relies on organic cation transporters (OCTs) for tissue penetration and therapeutic efficacy [189–191].”
BackgroundThe exposome and pancreatic cancer, lifestyle and environmental risk factors for PDAC
Peduzzi, G., Archibugi, L., Farinella, R., Pisani, R. P. D. L., Vodičková, Ľ., Vodička, P., Kraja, B., Sáinz, J., Bars‐Cortina, D., Daniel, N., et al. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.05.004 · Cited by 39
“This effect could be enhanced when metformin is used in combination with simvastatin, as shown in mouse models [219].”
Mechanisms underlying obesity-malignancy connection: a systematic narrative review
Sultana, A., & Rana, S. (2025) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-025-01084-9 · Cited by 28
“This particularly applies to obesity related cancers such as thyroid, breast, pancreatic, and colorectal cancers [130, 166, 222, 230].”
Obesity associated pancreatic ductal adenocarcinoma: Therapeutic challenges
Srilatha, M., Malla, R. R., Adem, M. P., Foote, J. B., & Nagaraju, G. P. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.11.002 · Cited by 21
Lv, H., Gong, H., Zhao, R., Gao, X., Liu, W., Zhao, L., & Sun, R. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118507 · Cited by 14
Metadata
- Authors
- Teper, Y., Ye, L., Waldron, R. T., Lugea, A., Sun, X., Sinnett-Smith, J., Hines, O. J., Pandol, S. J., Rozengurt, E., & Eibl, G.
- Affiliations
- University of California, Los Angeles (US)
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Eibl, Guido
- ORCID
- Venue
- Scientific Reports
- Published
- 2023-09-26
- Volume
- 13
- Issue
- 1
- Pages
- 16144-16144
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC10522691
- OpenAlex
- W4387038650
- Cited by
- 10
- References
- 49
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 2 · 2023: 1
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Veterans Affairs (I01 BX003801)
- Hirshberg Foundation for Pancreatic Cancer Research
- National Institutes of Health
- National Cancer Institute (R21CA258125, P01CA236585)
- National Institute of Allergy and Infectious Diseases (R21AI156592)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007180)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- metformin, simvastatin, combination therapy, pancreatic ductal adenocarcinoma, obesity, pancreatic intraepithelial neoplasia, Hippo signaling pathway, YAP, TAZ, drug repurposing, cancer prevention, high-fat high-calorie diet, synergistic antiproliferative effect
- MeSH terms
- Animals, Female, Male, Obesity, Pancreatic Neoplasms, Simvastatin, Carcinoma, Pancreatic Ductal, Mice, Adenocarcinoma in Situ
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low dosage combination treatment with metformin and simvastatin inhibits obesity-promoted pancreatic cancer development in male KrasG12D mice. https://app.cochat.ai/papers/10.1038/s41598-023-43498-9
- The paper
- Teper, Y., Ye, L., Waldron, R. T., Lugea, A., Sun, X., Sinnett-Smith, J., Hines, O. J., Pandol, S. J., Rozengurt, E., & Eibl, G. (2023). Low dosage combination treatment with metformin and simvastatin inhibits obesity-promoted pancreatic cancer development in male KrasG12D mice. Scientific Reports. https://doi.org/10.1038/s41598-023-43498-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.